321 related articles for article (PubMed ID: 23234585)
1. Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study.
Ruggiero S; Rafaniello C; Bravaccio C; Grimaldi G; Granato R; Pascotto A; Sportiello L; Parretta E; Rinaldi B; Panei P; Rossi F; Capuano A
J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):415-22. PubMed ID: 23234585
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.
Capuano A; Scavone C; Rafaniello C; Arcieri R; Rossi F; Panei P
Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S69-78. PubMed ID: 25171160
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.
Arcieri R; Germinario EA; Bonati M; Masi G; Zuddas A; Vella S; Chiarotti F; Panei P;
J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):423-431. PubMed ID: 23362511
[TBL] [Abstract][Full Text] [Related]
4. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
[TBL] [Abstract][Full Text] [Related]
5. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
[TBL] [Abstract][Full Text] [Related]
6. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
7. One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder.
Didoni A; Sequi M; Panei P; Bonati M;
Eur J Clin Pharmacol; 2011 Oct; 67(10):1061-7. PubMed ID: 21538145
[TBL] [Abstract][Full Text] [Related]
8. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
[TBL] [Abstract][Full Text] [Related]
9. Parental reporting of adverse drug reactions associated with attention-deficit hyperactivity disorder (ADHD) medications in children attending specialist paediatric clinics in the UK.
Tobaiqy M; Stewart D; Helms PJ; Williams J; Crum J; Steer C; McLay J
Drug Saf; 2011 Mar; 34(3):211-9. PubMed ID: 21332245
[TBL] [Abstract][Full Text] [Related]
10. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
11. Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
Pozzi M; Carnovale C; Mazhar F; Peeters GGAM; Gentili M; Nobile M; Radice S; Clementi E
J Clin Psychopharmacol; 2019; 39(4):386-392. PubMed ID: 31205193
[TBL] [Abstract][Full Text] [Related]
12. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder.
Fuentes J; Danckaerts M; Cardo E; Puvanendran K; Berquin P; De Bruyckere K; Montoya A; Quail D; Escobar R
J Clin Psychopharmacol; 2013 Dec; 33(6):766-74. PubMed ID: 23963057
[TBL] [Abstract][Full Text] [Related]
13. [ADHD register: post-marketing evaluation of the benefit-risk profile of drugs and promotion of the appropriateness].
Panei P; Arcieri R
Recenti Prog Med; 2013 Jun; 104(6):254-61. PubMed ID: 23801229
[TBL] [Abstract][Full Text] [Related]
14. Attention-deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study.
Germinario EA; Arcieri R; Bonati M; Zuddas A; Masi G; Vella S; Chiarotti F; Panei P;
J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):440-7. PubMed ID: 24024538
[TBL] [Abstract][Full Text] [Related]
15. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
[TBL] [Abstract][Full Text] [Related]
16. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
Niederhofer H
Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
[No Abstract] [Full Text] [Related]
17. Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
Hennessy S; Schelleman H; Daniel GW; Bilker WB; Kimmel SE; Guevara J; Cziraky MJ; Strom BL
Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):934-41. PubMed ID: 20623519
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
King S; Griffin S; Hodges Z; Weatherly H; Asseburg C; Richardson G; Golder S; Taylor E; Drummond M; Riemsma R
Health Technol Assess; 2006 Jul; 10(23):iii-iv, xiii-146. PubMed ID: 16796929
[TBL] [Abstract][Full Text] [Related]
19. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions.
Yildiz O; Sismanlar SG; Memik NC; Karakaya I; Agaoglu B
Child Psychiatry Hum Dev; 2011 Jun; 42(3):257-69. PubMed ID: 21165694
[TBL] [Abstract][Full Text] [Related]
20. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
Eiland LS; Bell EA; Erramouspe J
Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
